In one aspect, an entangled polymer composition includes an entangled polymer network including a plurality of entangled polymers; and a plurality of crosslinks crosslinking the polymers at a density of no more than one crosslink per 1,000 monomer units of the polymer; wherein the polymer composition has a toughness of at least about 100 Jm−2 and a stiffness of at least about 50 kPa.
C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
C08F 299/00 - Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
Disclosed are methods for diagnosing cancers using single-stranded DNA-damage associated small RNAs (sdRNAs). In some embodiments, methods for treating cancer including determining whether a subject has cancer using sdRNAs and administering a treatment to the subject. In some embodiments, the cancer is a BRCA1-dependent cancer. In some embodiments, the cancer involves changes to the BRCA1 protein as compared to non-cancerous cells.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus Veillonella, genus Faecalibacterium, genus Phascolarctobacteria, genus Oscillospira, genus Ruminococcus, genus Bacteroides, genus Blautia, family Christensenellaceae, genus Dialister, or phylum cyanobacteria.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
The inventions provided herein relate to detection reagents, compositions, methods, and kits comprising the detection reagents for use in detection, identification, and/or quantification of analytes in a sample. Such detection reagents and methods described herein allow multiplexing of many more labeled species in the same procedure than conventional methods, in which multiplexing is limited by the number of available and practically usable colors.
Methods and apparatuses are provided for evaluating a communication pathway connection. One of the methods includes generating a first voltage trace based on voltage peaks of a first node of a pair of nodes, the first voltage trace comprising a plurality of first voltage bursts over a period of time, the first voltage bursts each comprising a positive component and a negative component; generating a second voltage trace based on voltage peaks of a second node of the pair of nodes, the second voltage trace comprising a plurality of second voltage bursts over the period of time, the second voltage bursts each comprising a positive component and a negative component; applying the first voltage trace to a first electrode of a memristor; applying the second voltage trace to a second electrode of the memristor; measuring a final conductance of the memristor based on one or more pairs of time-correlated voltage bursts; determining a first conductance change corresponding to a difference between the final conductance and an initial conductance; determining a second conductance change corresponding to a difference between a normalization conductance and the initial conductance; and determining a strength of a communication pathway between the pair of nodes based on a ratio of the first conductance change to the second conductance change.
G06N 3/049 - Temporal neural networks, e.g. delay elements, oscillating neurons or pulsed inputs
G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
G11C 11/22 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using electric elements using ferroelectric elements
G11C 13/00 - Digital stores characterised by the use of storage elements not covered by groups , , or
G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron
8.
CONTROLLING ELECTRON BEAM INDUCED DEFECTS FOR LOW-LOSS PHOTONIC INTEGRATED CIRCUITS
Devices, systems, and methods are provided. In a first example embodiment, a device is provided. The device includes a substrate, and an optical waveguide. The substrate includes silicon dioxide. The substrate has a first surface and a second surface. The optical waveguide is disposed on the first surface of the substrate. The substrate includes a first region extending between the optical waveguide and the second surface of the substrate. The first region of the substrate includes a plurality of unpaired electron defects. In addition, a method of attenuating and optical signal with aspects of the device is provided. Additionally, a method of manufacturing the device is provided. A method of modulating an optical property of an aspect of the device is also provided.
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G02B 6/13 - Integrated optical circuits characterised by the manufacturing method
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
H10F 30/10 - Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices being sensitive to infrared radiation, visible or ultraviolet radiation, and having no potential barriers, e.g. photoresistors
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
9.
Gene Therapy Methods for Age-Related Diseases and Conditions
Methods of gene therapy are provided for treating or preventing age-related diseases or conditions by regulating one or more functional proteins associated with age-related diseases or conditions.
The present disclosure provides a contact-less detection using a cross-cavity device where a small dielectric sample is placed at its center. The optical properties of the sample, such as the Kerr and Faraday rotation, or polarizability, manifest in the coupling between the cavities' electromagnetic modes and in the shift of their resonant frequencies. By calculating the dynamics of what are referred to herein as geometrical photonic states, a measuring protocol is formulated based on the quantum metric that maximizes the Fisher information and isolates the individual components of the complex dielectric function.
The technology described herein is directed to methods and compositions for activating T cells, e.g., for use as a cancer vaccine. Said composition includes at least macrophage, at least one cancer antigen. The composition also may include at least one of LPS, GM-CSF, TNF-alpha, ILlbeta, IFN-alpha, CD40 agonist, poly (I:C), resiquimod, and/or IFN-gamma.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Pathogenic infections trigger a complex regulatory system of innate and adaptive immune responses designed to defend against the pathogen in the host organism. One of the many responses to pathogen invasion, e.g., viral, bacterial, fungal or parasitic infection, is the induction of interferon (IFN) production, a pleiotropic group of cytokines that play a critical role in human immune responses by ‘interfering’ with pathogen activity, e.g., viral replication, among others. Described herein are compositions and methods for inducing Type I interferon production. The compositions described comprise immunostimulatory complexes and RNA duplexes. Compositions comprising the immunostimulatory complexes and RNA duplexes described can be used for the treatment of diseases or disorders that respond to interferons.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
14.
NANOPORE-MATCHED PROTEIN SHUTTLE FOR MOLECULAR CHARACTERIZATION
Systems and methods are provided for trapping and electrically monitoring molecules in a nanopore sensor. The nanopore sensor comprises a support structure with a first and a second fluidic chamber, at least one nanopore fluidically connected to the two chambers, and a protein shuttle. The protein shuttle comprises an electrically charged protein molecule, such as Avidin. The nanopore can be a Clytosolin A. A method can comprise applying a voltage across the nanopores to draw protein shuttles towards the nanopores. The ionic current through each or all of the nanopores can be concurrently measured. Based on the measured ionic current, blockage events can be detected. Each blockage event indicates a capture of a protein shuttle by at least one nanopore. Each blockage event can be detected through a change of the total ionic current flow or a change in the ionic current flow for a particular nanopore.
C07K 5/03 - Peptides having up to four amino acids in a fully defined sequenceDerivatives thereof containing at least one abnormal peptide link in which at least a delta-amino acid is involved, e.g. isosteres
To infer transmission links using within-host variation, Applicants first developed a statistical model of minor variant frequencies, which Applicants fit to a dataset of 134,682 SARS- CoV-2 genomes from Massachusetts, USA. Applicants then combined this model with a stochastic epidemic process to develop a hierarchical Bayesian statistical model of viral outbreaks. After validating the approach on both synthetic and real outbreak datasets, Applicants applied the tool to 5,692 outbreak clusters among the 134,682 Massachusetts genomes. Applicants found that informative sub-consensus variants are relatively rare in outbreaks, but that when they do occur, they significantly help resolve transmission networks. Applicants methods and results demonstrate the utility of within-host variation for transmission inference of SARS-CoV-2 and other pathogens, stressing the importance of pathogen sequencing in epidemiology and public health.
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16B 10/00 - ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
17.
SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME
Mayo Foundation for Medical Education and Research (USA)
Inventor
Sinclair, David A.
Price, Nathan L.
Chini, Eduardo N.
Clardy, Jon C.
Cao, Shugeng
Abstract
The invention provides methods and compositions for inhibiting CD38 activity, and methods of treating or preventing various disorders associated with CD38 activity.
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 311/28 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.
H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
C07C 229/18 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
A metafluid includes a fluid exposed to a plurality of loads, each load of the plurality of loads causing a respective pressure change within the fluid. One or more compressible capsules are suspended within the fluid. Each capsule of the one or more compressible capsules has an external shell configured to withstand a cyclic elastic deformation. The external shell changes between a first shape and a second shape when a predetermined load occurs in the plurality of loads.
Systems and methods related to microfluidic devices (e.g., microfluidic devices comprising layers of films) are generally described. In some embodiments, a microfluidic device comprises a substrate configured to facilitate fluid transport, one or more intermediate layers disposed on the substrate, wherein the one or more intermediate layers are configured to define a plurality of fluidly connected microfluidic components, and a top layer disposed on the one or more intermediate layers. In certain embodiments, a microfluidic device comprises a microfluidic channel having a gap or area of increased hydrophobicity in between two separated portions of the channel to separately pin one or more liquids in one or more desired portions of the channel. According to some embodiments, a microfluidic device comprises a microfluidic channel with an inclined surface, such that different portions of the microfluidic channel are associated with different channel heights.
A previously uncharacterized gene and gene product are disclosed herein that increases blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
23.
TRIGGER NUCLEIC ACIDS AND RNA-BINDING PROTEINS FOR UPREGULATING GENE EXPRESSION
The present disclosure, at least in part, relates to compositions (e.g., engineered nucleic acids and engineered proteins) and methods for increasing gene expression. The engineered proteins include RNA-binding proteins (e.g., RNA-binding proteins that comprise a Interleukin Enhancer Binding Factor 3 (ILF3) sequence, a Cas sequence, or a combination thereof). In some aspects, the disclosure provides methods of identifying engineered nucleic acids that are shorter in length than a gene of interest to induce expression of the gene of interest and also provides RNA-binding proteins for inducing gene expression.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Described in certain example embodiments herein are compositions, such as immunogenic compositions that can contain or more viral polynucleotides and/or polypeptides. In some embodiments, the one or more viral polynucleotide is a non-canonical viral open reading frame (ORF). Also described herein are methods to identify one or more viral polynucleotides and/or polypeptides such as a non-canonical viral ORF, such as massively parallel ribosome profiling.
This invention provides methods of using phagocytic cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using phagocytic cells to identify markers of diseases or conditions.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
27.
DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues of organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provide dare methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
There is provided a system for environmental control in a building. The system includes a plurality of sensors including operational sensors and data gathering sensors, and a plurality of actuators. The system also includes a rule-based server and a data-driven server coupled to the plurality of sensors and the plurality of actuators. The rule-based server receives operation signals from the operational sensors, and control operation of the plurality of actuators according to one or more rules based on the operation signals. The data-driven server receives or monitors data signals from the data-gathering sensors and the operation signals from the operational sensors, trains and/or applies data-driven models to the data signals and the operation signals to predict performance changes in the building due to a command. In accordance with a determination that the performance changes meet a predetermined criteria, the data-driven server controls operations of the plurality of actuators according to the command.
H04L 67/125 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks involving control of end-device applications over a network
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.
A method of fabricating a functional construct for biological, robotic or other applications includes printing core-shell filaments into a support matrix, where each core-shell filament has an elongated core surrounded by a shell, and interconnecting the core-shell filaments to form branching and merging structures. Accordingly, an interconnected three-dimensional network of the core-shell filaments is formed within the support matrix. A tissue construct or other functional construct may be produced by this method.
32.
SYSTEMS, METHODS, AND CONTAINERS FOR FORMATION AND COLLECTION OF MICRON AND NANOMETER DIMENSION POLYMERIC FIBERS
Systems and methods for generation and collection of one or more a micron or nanometer dimension polymeric fiber and materials of such fibers are described herein. Some embodiments employ a substantially vertical aligned liquid bath layer generated by a rotating collection member for formation and collection of the fibers.
Aspects of the disclosure relate to systems, compositions, and methods for editing a DNA sequence encoding an endogenous tRNA by prime editing to produce a DNA sequence encoding a suppressor qtRNA. Additional aspects relate to compositions comprising the prime editing machinery and/or complexes comprising the prime editor and pegRNA that are capable of editing an endogenous tRNA into a suppressor qtRNA. In some aspects, the disclosure further relates to polynucleotides encoding one or more nucleic acid sequences encoding the prime editor and/or pegRNA, cells comprising the polynucleotides and complexes comprising the prime editor and pegRNA, kits comprising any one of the compositions, complexes, polynucleotides, vectors and/or cells disclosed herein, and/or delivery systems for administering any one of the compositions, complexes, polynucleotides, or vectors to a subject in need thereof. Additional aspects relate to methods for inserting a new suppressor qtRNA gene into a target site in a genome using prime editing.
The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and/or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).
Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for engineering Cas9 and Cas9 variants that have increased activity on target sequences that do not contain the canonical PAM sequence. In some embodiments, fusion proteins comprising such Cas9 variants and nucleic acid editing domains, e.g., deaminase domains, are provided.
Provided herein are methods of treating or preventing the transmission of Herpes Simplex Virus (HSV) in a subject, the method comprising administering to the subject a composition comprising a L. crispatus bacteria and/or a peptidoglycan disclosed herein.
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In son embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
An apparatus can include a computational imaging system configured to output a plurality of features. The apparatus can include one or more processors configured to receive the plurality of features, apply the plurality of features as input to a classifier to cause the classifier to output a first performance metric, apply the plurality of features as input to the classifier to cause the classifier to output a plurality of performance metrics, and/or calculate a p-value based on the first performance metric and/or the plurality of performance metrics.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
39.
TRANSCRIPTOMIC SIGNATURES FOR IDENTIFYING DRUG-SUSCEPTIBLE MYCOBACTERIUM TUBERCULOSIS COMPLEX
Techniques are provided for determining whether a biological sample obtained from a patient contains bacteria, such as My cobacterium tuberculosis complex, susceptible to treatment by a particular antibiotic performed at least in part by using at least one computer hardware processor to obtain RNA expression data for the biological sample previously- obtained by profiling RNA from the biological sample after exposure to the at least one antibiotic, and for each particular antibiotic: determine whether a particular transcriptomic signature for the particular antibiotic is present in the RNA expression data, wherein the particular transcriptomic signature includes at least some bacterial genes previously determined to be upregulated and/or downregulated in response to exposure to the particular antibiotic, and when it is determined that the transcriptomic signature is present in the RNA expression data, determining that the bacteria in the biological sample is susceptible to treatment by the particular antibiotic.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
40.
SYSTEMS, ARTICLES, AND METHODS RELATED TO DIELECTRIC ELASTOMERS
Certain aspects of this disclosure relate to systems, articles, and methods involving dielectric elastomers. In some embodiments, a first layer comprising an elastomer (e.g., a dielectric elastomer) may be disposed on a second layer (e.g., an electrode layer). In some embodiments, the device is a dielectric elastomer actuator comprising a first layer comprising an elastomer, a second layer comprising a first plurality of particles and a second plurality of particles, and a third layer comprising the first plurality of particles and the second plurality of particles. In some embodiments, a first region of the second and/or third layer comprises the first plurality of particles. In some embodiments, a second region of the second and/or third layer comprises the second plurality of particles. In some embodiments, electrodes of the dielectric elastomer actuator may have suitable contact resistances to allow for advantageous response speeds and relatively high breakdown strengths.
G01L 1/14 - Measuring force or stress, in general by measuring variations in capacitance or inductance of electrical elements, e.g. by measuring variations of frequency of electrical oscillators
G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
41.
CATHODE INTERFACE COATING LAYERS FOR SOLID STATE BATTERIES
The invention provides compounds that can be used as cathode interface coating layers in solid state batteries. The compounds disclosed herein provide enhanced dynamic stability.
Disclosed herein are methods for improving the viability of a dental implant in a subject with jawbone deterioration. The methods include treatment of the subject with abaloparatide prior to performing dental implant surgery.
Disclosed herein are binding molecules and/or antibodies targeting a universal influenza antigen and methods of using the same to treat a subject having an influenza infection and to minimize the progression of an influenza infection in a subject.
The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
The present disclosure relates to therapeutic methods and clinically useful molecular switches, for which activity or degradation of a switch-presenting polypeptide can be precisely induced via administration or withdrawal of an FDA-approved drug. Certain aspects of the disclosure relate to an engineered drug-inducible heterodimeric system including a first polypeptide presenting a CRBN polypeptide disrupted for or lacking a DDB1-interacting domain and a second polypeptide presenting a CRBN polypeptide substrate, where binding between the CRBN polypeptide and the CRBN polypeptide substrate are inducible via administration of an FDA-approved thalidomide analog immunomodulatory drug (IMiD). Another aspect of the disclosure relates to a chimeric antigen receptor (CAR) that presents a minimal fragment of the CRBN polypeptide substrate IKZF3 capable of triggering proteasomal degradation of CAR upon administration of an FDA-approved IMiD.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Green, Alexander
Braff, Dana
Takahashi, Melissa
Pardee, Keith
Collins, James J.
Lambert, Guillaume
Ferrante, Thomas
Abstract
Methods for detecting the presence of a pathogen infection are described. In particular, this document provides a method of detecting target nucleic acids, such as pathogen-specific RNA, in a biological sample obtained from a subject, where the method comprises using one or more toehold switch sensors and an isothermal amplification step to detect the target nucleic acid. Methods specific for detecting and identify the presence of a virus such as Zika virus are also provided.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
Systems and methods are disclosed for making a quantum network node. A plurality of scoring function F values are calculated for an array of at least two photonic crystal cavity unit cells, each having a lattice constant α and a hole having a length Hx and a width Hy. A value of α, a value of Hx, and a value of Hy are selected for which a scoring function value is at a maximum. A waveguide region and the array of at least two photonic crystal cavity unit cells based on the selected values are formed on a substrate. At least one ion between a first photonic crystal cavity unit cell and a second photonic crystal cavity unit cell are implanted and annealed into a quantum defect. A coplanar microwave waveguide is formed on the substrate in proximity to the array of at least two photonic crystal cavity unit cells.
The disclosure provides methods useful for treating and/or preventing muscular dystrophies, such as Duchenne's muscular dystrophy (DMD), and/or other muscle wasting disorders by modulating prolyl hydroxylase 3 (PHD3).
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present invention generally relates to systems and methods for imaging or determining nucleic acids, for instance, within cells. In some embodiments, the transcriptome of a cell may be determined. Certain embodiments are directed to determining nucleic acids, such as mRNA, within cells at relatively high resolutions. In some embodiments, a plurality of nucleic acid probes may be applied to a sample, and their binding within the sample determined, e.g., using fluorescence, to determine locations of the nucleic acid probes within the sample. In some embodiments, codewords may be based on the binding of the plurality of nucleic acid probes, and in some cases, the codewords may define an error-correcting code to reduce or prevent misidentification of the nucleic acids. In certain cases, a relatively large number of different targets may be identified using a relatively small number of labels, e.g., by using various combinatorial approaches.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
51.
Humam-Wearable Device Including a Sensor-Actuated Soft Actuator and Method for Actuation
A wearable device includes at least one soft actuator body incorporated into the device and defining a chamber. A fluid connector is positioned and configured to provide a path for fluid flow into and out of the chamber. A control system is connected with the soft actuator body and comprises a pneumatic or hydraulic pump, valves, and a microcontroller and is configured to control fluid flow through the fluid connector into and out of the chamber to produce at least one actuation motion selected from bending, extending, stiffening, expansion, contraction, twisting, and combinations thereof in the soft actuator body. At least one sensor, including a motion sensor, is incorporated into the device and is in communication with the microcontroller, which is configured to control the fluid flow based on communications from the at least one sensor, including the motion sensor, and to thereby control actuation of the soft actuator body.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61H 1/02 - Stretching or bending apparatus for exercising
A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type
The present invention generally relates to systems and methods for imaging or determining nucleic acids, for instance, within cells. In some embodiments, the transcriptome of a cell may be determined. Certain embodiments are directed to determining nucleic acids, such as mRNA, within cells at relatively high resolutions. In some embodiments, a plurality of nucleic acid probes may be applied to a sample, and their binding within the sample determined, e.g., using fluorescence, to determine locations of the nucleic acid probes within the sample. In some embodiments, codewords may be based on the binding of the plurality of nucleic acid probes, and in some cases, the codewords may define an error-correcting code to reduce or prevent misidentification of the nucleic acids. In certain cases, a relatively large number of different targets may be identified using a relatively small number of labels, e.g., by using various combinatorial approaches.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
The present invention generally relates to systems and methods for imaging or determining nucleic acids, for instance, within cells. In some embodiments, the transcriptome of a cell may be determined. Certain embodiments are directed to determining nucleic acids, such as mRNA, within cells at relatively high resolutions. In some embodiments, a plurality of nucleic acid probes may be applied to a sample, and their binding within the sample determined, e.g., using fluorescence, to determine locations of the nucleic acid probes within the sample. In some embodiments, codewords may be based on the binding of the plurality of nucleic acid probes, and in some cases, the codewords may define an error-correcting code to reduce or prevent misidentification of the nucleic acids. In certain cases, a relatively large number of different targets may be identified using a relatively small number of labels, e.g., by using various combinatorial approaches.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
54.
ELECTROCHEMICAL MEASUREMENT APPARATUSES AND METHODS FOR MONITORING AND CONTROLLING PH
An electrochemical apparatus includes an array of pixels disposed on a chip, stimulator circuitry disposed on the chip and configured to provide electrical input signals to cause stimulation of the pixels of the array, and sensor circuitry disposed on the chip and configured to read electrical output signals from the pixels of the array. The stimulator circuitry is configured to provide the input signals to cause stimulation of the pixels individually, and the sensor circuitry is configured to selectively read the output signals from the pixels while the pixels are being stimulated. The sensor circuitry is configured to measure an open-circuit voltage at each of the pixels and a current flow at each of the pixels while the pixels are being stimulated by the stimulator circuitry. The open-circuit voltage may be measured while the current flow is being measured.
Cas-cleavable reporter systems, CRISPR-Cas systems thereof, and methods of use thereof in CRISPR-Cas based diagnostics. Cas-cleavable reporter systems may generate a luminescent, fluorescent, or other detectable signal upon Cas-collateral cleavage of one or more reporter system components. CRISPR-Cas systems may comprise a Cas protein having collateral cleavage activity, guide molecules, and the Cas-cleavable reporter system. Cas-cleavable reporter systems may be a split luciferase reporter system, at least one element of which is bound to beads. For multiplexing, CRISPR-Cas systems may comprise a Cas-cleavable quenched reporter system, optionally a Cas-cleavable quenched fluorescent reporter system, a Cas protein having collateral cleavage activity, and target-specific guide molecules attached to color-coded beads. CRISPR-Cas systems may further comprise amplification reagents. Methods may apply said CRISPR-Cas systems to flow cell, well-plate, or other devices, and may measure detectable signals by microscopic, plate reader, or other methods.
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent, and/or diagnose cancerous or infectious conditions and disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
57.
SYSTEM AND METHOD FOR CONTROLLING A WEARABLE ROBOTIC DEVICE
Systems and methods related to the operation of wearable robotic systems are disclosed. In one embodiment, a user intention model is developed to accurately identify the intentions of a user in real-time. Utilizing data from multiple wearable sensors, including Inertial Measurement Units (IMUs) and capacitive deformation sensors, a neural network-based approach is employed to capture both kinematic-related and kinetic-related signals. This intention model aims to enhance the accuracy and reliability of movement identification, enabling more effective control of the exoskeleton. In one embodiment, the effects of hysteresis in the exoskeleton system are addressed through the implementation of the Preisach model. By integrating the Preisach model into the control approach, the effects of hysteresis are mitigated, enabling accurate prediction of the required pressure for delivering support to the individual user. By accurately identifying user intentions in real-time and compensating for hysteresis effects, the exoskeleton's performance is optimized.
In one aspect, a conduit includes: an elongated body having a proximal end and a distal end; a lumen; a plurality of inlets disposed on the elongated body that allow fluid flow through the inlets; and at least one flange extending outwardly from the elongated body, wherein the at least one flange extends at an angle other than 90 degrees from a length of the elongated body. In one aspect, a conduit includes: an elongated body having a proximal end and a distal end; a lumen; and a plurality of inlets disposed on the elongated body that allow fluid flow through the inlets; wherein at least one of the plurality of inlets has an outer diameter and an inner diameter, wherein the outer diameter is larger than the inner diameter.
A method is provided for deterministically translocating through a nanopore a target polymer molecule of a nucleic acid polymer molecule or a protein polymer molecule. In the method, an enzyme clamp is reversibly bound to a plurality of sequential polymer subunits of the target polymer molecule. The target polymer molecule and the enzyme clamp are disposed at the nanopore. In the method, there is applied a pulse of force operative to deterministically advance the enzyme clamp along the target polymer molecule by no more than one polymer subunit. The pulse of force is then repeatedly applied to cause deterministic translocation of a sequential plurality of polymer subunits of the target polymer molecule through the nanopore.
Provided herein are methods of treating or ameliorating an immune-related adverse event associated with an immunotherapy or immune-modulating therapy in a subject with cancer, autoimmune disease or other condition requiring immune-modulating agents, the method comprising administering to the subject an agent that modulates the activity or expression of TIGIT.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.
In some aspects, the present disclosure provides methods and compositions for isothermal low temperature amplification of target polynucleotides, and detection thereof.
Scents are perceived by the olfactory sensory neurons (OSNs) that line the upper nasal cavity. Each OSN expresses one odorant receptor, and these odorant receptors contact the scent molecules. Methods for determining which odorant receptor(s) are activated by a scent are lacking, making it difficult to replicate or improve scents. The technology as disclosed herein refers to methods relating to activating odor response genes found in olfactory sensory neurons after the neurons are exposed to at least one volatilized chemical compound.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
66.
SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
In some aspects, a device comprises a plurality of walls defining one or more channels; wherein the one or more channels have a cross-section in a plane perpendicular to a vertical axis of the device that changes along the vertical axis; and one or more floats sized to allow movement of the one or more floats within said one or more channels, wherein the one or more floats have a surface characteristic that is different from the surface characteristic of the walls such that, upon contact with a fluid, said walls and said floats form different contact angles and induce a repulsive capillary force between the walls and the one or more floats at a surface of the fluid.
The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome, or for treating touch over-reactivity, pain, or mechanical allodynia.
Some aspects are generally related to articles comprising a lipid membrane (e.g., a vesicle) and a glycolipid at least partially embedded within the lipid membrane. In some cases, the glycolipid may be an agonist for a receptor and/or change at least one property of the article comprising the lipid membrane, which may make the article more suitable for associating with cells and/or being endocytosed by cells. In some cases, the lipid membranes may encapsulate entities such as small molecules, DNA and/or proteins, and thus the article may be suitable for drug delivery or other applications. Some aspects are related to articles comprising multiple glycolipids, which may impart various properties to the articles, for example, decreased zeta potentials and/or altered surface diffusion rates of lipids of the article. Still other aspects are generally directed to methods of making or using the articles, kits comprising the articles, or the like.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Parallel uses of microfluidic methods and devices for focusing and/or forming discontinuous sections of similar or dissimilar size in a fluid are described. In some aspects, the present invention relates generally to flow-focusing-type technology, and also to microfluidics, and more particularly parallel use of microfluidic systems arranged to control a dispersed phase within a dispersant, and the size, and size distribution, of a dispersed phase in a multi-phase fluid system, and systems for delivery of fluid components to multiple such devices.
B01F 33/3011 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions using a sheathing stream of a fluid surrounding a central stream of a different fluid, e.g. for reducing the cross-section of the central stream or to produce droplets from the central stream
The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative diseases and cancer, are also provided.
C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The invention relates to a monomeric immunogen comprising one receptor binding domain of a Coronavirus spike protein, wherein the receptor binding domain includes at least 4 non-native. N-linked, glycosylation sites.
The present disclosure relates to methods aimed towards non-invasive targeted genomic and epigenomic sequencing of spatially-defined cellular or subcellular region. More particularly, the present disclosure relates to methods of using photoselection to achieve non-invasive targeted genomic and epigenomic sequencing of spatially-defined cellular or subcellular regions, via the use of light-activated probes.
Systems and methods for focused direction deposition of a micron or nanometer dimension polymeric fiber and materials of such fibers are described herein. Systems and methods employ one or more gas flows to entrain and deflect fibers produced by a rotary jet spinning system forming a focused fiber stream. Some embodiments enable control of alignment and distribution of the fibers with a relatively high fiber throughput.
Provided are isolated enhancer element sequences that regulate and restrict expression of a transgene, such as a therapeutic gene, to certain neuronal cell types and/or populations in the brain and CNS. Therapeutic virus vectors containing the cloned enhancer element sequences, particularly, recombinant adeno-associated virus (rAAV) vectors, and a transgene are described. The rAAV vectors, compositions and methods are useful for treating subjects afflicted with neuropsychiatric and neuropathological diseases, disorders and conditions and symptoms thereof. The vectors can be used to restore normal cellular function, e.g., by restoring expression of certain genes to the appropriate interneuron or neuron target cell populations, to address the root cause of the disease, e.g., by restoring the excitation-inhibition balance in the neuronal cell or cell population.
The compositions and methods described herein are related to the identification of disease related genes, the expression of which involves a fraction of transcripts with a retained intron, comprising antisense oligonucleotides (ASO) compositions and methods that target genes which meet two criteria: the genes have a fraction of transcripts that retains an intron, and haploinsufficiency of the gene is associated with disease.
The present disclosure relates, at least in part, to methods and cells useful for promoting ubiquitination-independent protein degradation and for promoting protein stability using an engineered midnolin protein.
e.g.e.g., a muscle) in the human. Electronic circuits process these signals to decouple them based on frequency. A method using this system involves placing electrodes on human skin, generating and delivering a higher-frequency AC electrical signal, receiving and processing the higher-frequency electrical frequency and a lower-frequency bioelectrical signal to decouple the signals, to estimate impedance, and to calculate electrophysiological activity in the human.
222, wherein the redox-active species includes a substituent that forms an intramolecular hydrogen bond in the reduced state. The method is safe, scalable, and potentially inexpensive, as it utilizes non-volatile and potentially low-cost redox organic and inexpensive inorganic species and can operate at ambient temperature and pressure and can operate at high current densities.
H01M 10/0564 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes the electrolyte being constituted of organic materials only
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
81.
METHODS OF INHIBITING HSP90AB1 FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
An optical component comprises a metasurface comprising nanoscale elements. The metasurface is configured to receive incident light and to generate optical outputs. The geometries and/or orientations of the nanoscale elements provide a first optical output upon receiving a polarized incident light with a first polarization, and provide a second optical output upon receiving a polarized incident light with a second polarization that is different from the first polarization.
G03H 1/02 - Holographic processes or apparatus using light, infrared, or ultraviolet waves for obtaining holograms or for obtaining an image from themDetails peculiar thereto Details
83.
Engineered liposome with cell membrane proteins to reduce melanosome transport
The present disclosure discloses an engineered liposome with cell membrane proteins to reduce melanosome transport and a preparation method thereof, and belongs to the technical field of cosmetics and biomedicine. The present disclosure provides the engineered liposome with cell membrane proteins to reduce melanosome transport and the preparation method thereof, which is easy to operate, requires no large-scale equipment, has few additives, and a preparation process is simple and environmentally friendly. The biomimetic liposome can significantly inhibit melanin transport. The fluorescence intensity of melanosomes in keratinocytes is found to decrease by 3.5-fold in a co-culture test of melanocytes and the keratinocytes, indicating that this biomimetic liposome is very effective in inhibiting accumulation of melanin in skin keratinocytes. These findings provide an effective strategy for reducing melanosome transfer to treat hyperpigmentation, while also introducing an alternate approach for regulating cellular communication of extracellular vesicles and organelles.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventor
Knipe, David M.
Tran, Thao
Glorioso, Joseph C., Iii
Deluca, Neal A.
Abstract
Provided herein is a herpes simplex virus 1 (HSV-1) recombinant virus, comprising one or more therapeutic payload sequences, wherein the genome comprises at least one alteration in each of a gene encoding infected cell polypeptides (ICP)0, a gene encoding ICP4, a gene encoding ICP22, a gene encoding ICP27 and a gene encoding ICP47, wherein the genome does not encode a functional ICP0, ICP4, ICP22, ICP27 and ICP47 protein, and wherein the genome comprises internal inverted repeat (joint) regions. Methods for using the same are also provided.
The present disclosure generally relates to the amplification of RNA, e.g., for MERFISH or other applications. One set of embodiments is generally directed to a method of synthesizing a nucleic acid. Some embodiments are drawn to systems and methods for in situ amplification of RNA, which may allow genome-scale imaging of RNAs, including short RNAs and RNA isoforms that are differentiated by short sequences. In some embodiments, RNA such as mRNA may be transcribed into cDNA using a reverse transcriptase. The reverse transcriptase can also be used to associate a promoter (for example, a T7 promotor)with the RNA, e.g., by using a template-switching oligonucleotide (TSO). The promotor sequence can then be used to amplify the RNA, e.g., using techniques such as in vitro transcription, which can be performed in situ. Having amplified or increased amounts of RNA in situ may be useful for certain applications, such as MERFISH, as the RNA is easier to detect. Other aspects are generally related to methods for using such techniques, kits involving such techniques, or the like.
Provided herein, in some embodiments, are methods, compositions and kits for controlling nucleation and assembly of molecular nanostructures, microstructures and macrostructures.
The present invention provides novel peripherally-restricted benzodiazepines with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.
F25B 23/00 - Machines, plants or systems, with a single mode of operation not covered by groups , e.g. using selective radiation effect
C07C 211/15 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 211/63 - Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
C07C 215/08 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
C07C 217/08 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.
Exemplary embodiments provide systems, devices and methods for the fabrication of three-dimensional polymeric fibers having micron, submicron and nanometer dimensions, as well as methods of use of the polymeric fibers.
Described in embodiments herein are thiol-ene polymeric compositions that exhibit photo-induced, reversible switching between a solid (e.g., elastomeric) state and a liquid (e.g., flowable) state. The thiol-ene polymeric compositions may comprise a vinyl oligomer comprising at least two vinyl groups, a thiol oligomer comprising at least two thiol groups, and a Type I photoinitiator. In some embodiments, the composition comprises an excess of thiol groups relative to vinyl groups (e.g., a ratio of thiol groups to vinyl groups in the composition is at least 3:1). Reversible switching between the solid state and the liquid state may be induced through exposure of the composition to electromagnetic radiation (e.g., ultraviolet (UV) radiation). In some cases, reversible switching may be induced by a relatively low amount of energy (e.g., about 1 J/cm2 or less).
The present invention generally relates to droplets and/or emulsions, such as multiple emulsions. In some cases, the droplets and/or emulsions may be used in assays, and in certain embodiments, the droplet or emulsion may be hardened to form a gel. In some aspects, a heterogeneous assay can be performed using a gel. For example, a droplet may be hardened to form a gel, where the droplet contains a cell, DNA, or other suitable species. The gel may be exposed to a reactant, and the reactant may interact with the gel and/or with the cell, DNA, etc., in some fashion. For example, the reactant may diffuse through the gel, or the hardened particle may liquefy to form a liquid state, allowing the reactant to interact with the cell. As a specific example, DNA contained within a gel particle may be subjected to PCR (polymerase chain reaction) amplification, e.g., by using PCR primers able to bind to the gel as it forms. As the DNA is amplified using PCR, some of the DNA will be bound to the gel via the PCR primer. After the PCR reaction, unbound DNA may be removed from the gel, e.g., via diffusion of washing. Thus, a gel particle having bound DNA may be formed in one embodiment of the invention.
B01F 33/3011 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions using a sheathing stream of a fluid surrounding a central stream of a different fluid, e.g. for reducing the cross-section of the central stream or to produce droplets from the central stream
B01F 33/302 - Micromixers the materials to be mixed flowing in the form of droplets
B01F 101/23 - Mixing of laboratory samples e.g. in preparation of analysing or testing properties of materials
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Aspects of the disclosure provide nucleic acids and compositions comprising gene regulatory elements (GREs) for specific expression in nociceptor cells. Other aspects of the disclosure relate to the use of vectors and compositions comprising the gene regulatory elements for treating or managing pain and other neurological diseases in a subject in need thereof.
Described herein are compositions and methods of use related to oligonucleotides with modified nucleic acid backbones and conjugated to cell penetrating peptides that are complementary to 5'-GGTGGTGG-3' for the treatment of antibiotic-resistant bacterial infection.
Systems and methods are provided for implementing a verifiable transaction block on an exchange, the verifiable transaction block including transactions (e.g., purchases and/or sales) that are to be executed on the exchange in accordance with an ordering of the transactions. The techniques provided include ordering, using a verifiable sequencing rule, the transactions of the set of transactions to obtain a transaction block of ordered transactions, and causing the execution of the ordered transactions. The transactions may indicate a purchase and/or a sale of at least one token of two or more tokens on a liquidity pool.
G06Q 20/40 - Authorisation, e.g. identification of payer or payee, verification of customer or shop credentialsReview and approval of payers, e.g. check of credit lines or negative lists
G06Q 20/36 - Payment architectures, schemes or protocols characterised by the use of specific devices using electronic wallets or electronic money safes
Provided herein are methods of rejuvenating, restoring cellular function to, decreasing the biological age of, decreasing the apparent chronological age of, and reprogramming cells, organs, and tissues, using chemical cocktails comprising two or more compounds described herein, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof. Also provided herein are methods of treating a disease, methods of monitoring cellular aging, and pharmaceutical compositions and kits using two or more compounds described herein, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, or prodrugs thereof.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
99.
Use of Metasurface Optical Components to Alter Incident Light
Metasurface optical components deposited on the surface of a substrate are used to alter incident light. The metasurface optical components comprise a pattern of silicon dielectric resonators that have nonperiodic gap distances between adjacent silicon dielectric resonators; and each silicon dielectric resonator is an elongated rectangular prism that has a width, a length, and a thickness. Incident light is directed to the metasurface optical components, wherein the gap distances, the widths, and the thicknesses are configured to scatter the incident light and impart a phase shift, ranging at least from 0 to 2π, on an outgoing light. Each dielectric resonator has a rectangular cross-section in a plane perpendicular to the substrate surface such that a first phase shift is imparted for a transverse-electric (TE) component of the incident light and a second phase shift is imparted for a transverse-magnetic (TM) component of the incident light.
H01Q 15/10 - Refracting or diffracting devices, e.g. lens, prism comprising three-dimensional array of impedance discontinuities, e.g. holes in conductive surfaces or conductive discs forming artificial dielectric
100.
MICROPOROUS PARTICLES TO ENHANCE GAS TRANSPORT IN MEMBRANES
This invention provides membranes including a polymer having dispersed therein a plurality of microporous particles. The membranes improve mass transport in polymer electrolyte fuel cells.
